Colorectal Neoplasms

Oncology·MeSH: Colorectal Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

25 drugs in development·7 companies·32 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
levoleucovorin	Amneal Pharmaceuticals, Inc. (AMRX)
zaltrap	Sanofi (SNY)

Phase 3(15)

Drug	Company
Amivantamab	Amneal Pharmaceuticals, Inc. (AMRX)
Amivantamab	REGENXBIO Inc. (RGNX)
Amivantamab and Recombinant Human Hyaluronidase	Amneal Pharmaceuticals, Inc. (AMRX)
Camrelizumab and Cetuximab	Amneal Pharmaceuticals, Inc. (AMRX)
cetuximab	GH Research PLC (GHRS)
Cetuximab	Merck & Co., Inc. (MRK)
Cetuximab	REGENXBIO Inc. (RGNX)
Cetuximab	Amneal Pharmaceuticals, Inc. (AMRX)
eflornithine plus sulindac	GH Research PLC (GHRS)
Floxuridine	IGM Biosciences, Inc. (IGMS)
folfiri	Sanofi (SNY)
folfiri	GH Research PLC (GHRS)
leucovorin calcium/levoleucovorin	GH Research PLC (GHRS)
Leucovorin calcium/Levoleucovorin	REGENXBIO Inc. (RGNX)
Tucatinib	PFIZER INC (PFE)

Phase 2(1)

Drug	Company
cetuximab	PFIZER INC (PFE)

Phase 1(5)

Phase 1/Phase 2(1)

Drug	Company
tisotumab vedotin	PFIZER INC (PFE)

Phase 4(1)

Drug	Company
Xeloda	IGM Biosciences, Inc. (IGMS)

BioSniper tracks 25 drugs in development for Colorectal Neoplasms across 7 companies.

There are 32 clinical trials targeting Colorectal Neoplasms tracked by BioSniper.

The estimated prevalence of Colorectal Neoplasms is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.